Hangzhou Miracogen

Hangzhou Miracogen is a clinical-stage biotechnology company specializing in the discovery and development of next-generation antibody-drug conjugates (ADCs) for oncology. The company utilizes a proprietary site-specific conjugation technology platform to design therapeutic candidates with enhanced stability, potency, and safety profiles. Its lead program, MRG003, is a first-in-class EGFR-targeting ADC currently undergoing mid-to-late-stage clinical evaluation for nasopharyngeal carcinoma and other solid tumors. Another key asset, MRG002, targets HER2 and is being evaluated for breast and gastric cancers. In 2020, Miracogen was acquired by Lepu Biopharma, integrating its robust ADC pipeline and technical expertise into Lepu's broader oncology portfolio. The company continues to advance its diverse pipeline through global clinical development programs.